Brief: Mainz Biomed Reports Positive Topline Results From U.S. Eaarly Detect Study Evaluating Novel MRNA Biomarkers
05/12/2023 16:32
Dec 5 (Reuters) - Mainz Biomed NV 4TO.F :
* MAINZ BIOMED REPORTS POSITIVE TOPLINE RESULTS FROM U.S.
EAARLY
DETECT STUDY EVALUATING NOVEL MRNA BIOMARKERS
* MAINZ BIOMED NV - TRIAL IS ON TRACK TO COMMENCE ENROLLMENT
IN
MID-2024
* MAINZ BIOMED NV - RESULTS DEMONSTRATE SENSITIVITY FOR
COLORECTAL
CANCER OF 97% WITH SPECIFICITY OF 97% AND ADVANCED ADENOMA
SENSITIVITY OF 82%
Further company coverage: 4TO.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing